Edinburgh BioQuarter appoints commercialisation director
pharmafile | March 16, 2010 | Appointment | Research and Development | Edinburgh BioQuarter, appointment, research and development
Dr Michael Capaldi has joined Scottish life sciences research hub Edinburgh BioQuarter as director of commercialisation.
He will lead a team of up to 15 people to drive forward an ambitious £12 million commercialisation project that aims to bridge the gap between industry demands and the research being carried out in Scotland.
This will see Dr Capaldi manage industry relationships with global pharmaceutical and biotech companies and lead efforts to generate new spinout companies from the University of Edinburgh’s College of Medicine and Veterinary Medicine, based within the Edinburgh BioQuarter.
Professor Sir John Savill, head of the College of Medicine and Veterinary Medicine at the University of Edinburgh, said: “Michael Capaldi brings a great strength of knowledge to Edinburgh BioQuarter, encompassing commercial and management expertise as well as a scientific background.
“His experience in the Life Sciences sector and his strong track record in raising capital from private and public markets to fund early stage biotechnology companies will be of enormous benefit in driving commercialisation opportunities forward.”
Dr Capaldi’s background includes over 26 years experience in the pharmaceutical and life sciences industries in the UK, Europe and the US.
During this time he held chief executive posts with Hunter-Fleming, Scancell and Synaptica, and senior management posts with Core Group and Amersham International.
Related Content
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …
